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Education and debate
CONSORT statement:
extension to cluster randomised trials
Marion K Campbell, Diana R Elbourne, Douglas G Altman for the CONSORT Group
Reports of cluster randomised trials require additional
information to allow readers to interpret them
accurately
The effective reporting of randomised controlled
trials has received useful attention in recent years.
Many journals now require that reports conform to the
guidelines in the Consolidated Standards of Reporting
Trials (CONSORT) statement, first published in 19961
and revised in 2001.2 The statement includes a
checklist of items that should be included in the trial
report. These items are evidence based whenever pos-
sible and are regularly reviewed.3 The statement also
recommends including a flow diagram to show the
flow of participants from group assignment through to
the final analysis.
The CONSORT statement focused on reporting
parallel group randomised trials in which individual
participants are randomly assigned to study groups.
However, in some situations it is preferable to
randomly assign groups of individuals (such as
families or medical practices) rather than individuals.
Reasons include the threat of contamination of some
interventions (such as dietary interventions) if
individual randomisation is used.4 5 Also, in certain
settings randomisation by group may be the only fea-
sible method of conducting a trial.6 Trials with this
design are variously known as field trials, community
based trials, place based trials, or (as in this paper)
cluster randomised trials.7 In an earlier discussion
paper we considered the implications of the
CONSORT statement for the reporting of cluster ran-
domised trials.8 Here we present updated guidance,
based on the 2001 revision of the CONSORT
statement.2
Methodological issues in cluster
randomised trials
Compared with individually randomised trials, cluster
randomised trials are more complex to design, require
more participants to obtain equivalent statistical
power, and require more complex analysis. The meth-
odological issues in cluster randomised trials have
been widely discussed.7 9 In brief, observations on indi-
viduals in the same cluster tend to be correlated (non-
independent), and so the effective sample size is less
than the total number of individual participants.
The reduction in effective sample size depends on
average cluster size and the degree of correlation
within clusters, known as the intracluster (or intraclass)
correlation coefficient (). The intracluster correlation
coefficient is the proportion of the total variance of
the outcome that can be explained by the variation
between clusters. To retain power, the sample size
should be multiplied by 1+(m − 1), called the design
effect, where m is the average cluster size. Hayes and
Bennett describe a related coefficient of variation, k,
between clusters10 and Connelly considers an
economic approach.11 Software is available to adjust
for the intracluster correlation coefficient in an
analysis.12
The conduct of cluster randomised controlled trials
may also differ from that of trials that randomise indi-
viduals. For instance, clusters are usually randomised
all at once (or in batches) rather than one at a time.
After randomisation, individuals in the clusters may be
approached for consent, which raises the possibility of
post-randomisation selection bias,4 or they may not,
which raises ethical concerns.13 14 An expanded
explanation of the methods of cluster randomised
trials is available on the CONSORT website (www.
consort_statement.org).
Quality of reporting of cluster trials
Surveys of published cluster trials have found that their
conduct and reporting have been poor. Of 21 cluster
trials identified in two major public health journals,
only four (19%) had accounted for the clustering in the
planning of the trial.15 Similarly, in a review of
physicians’ patient care practices, 70% (38/54) of the
identified studies had not appropriately accounted for
the clustered nature of their study data in their
analysis.16 Of 16 cluster trials reviewed by Donner et al,
only four provided any rationale for adopting a
clustered design, only three accounted for clustering in
the sample size calculations, and only eight accounted
for clustering in the analysis.17
Recent studies have shown continuing problems
with the design and analysis of cluster trials; 42% (62/
149) of trials of implementation research interven-
tions did not account appropriately for the clustering
in their design,18 and 42% (10/24) of trials of clinical
decision support systems did not appropriately
account for clustering in their analysis (none
accounted for clustering in their sample size
calculations).19 A recent review of 51 cluster ran-
domised trials conducted in sub-Saharan Africa
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published in the past 30 years showed only 10 trials
took clustering into account in sample size or power
calculations, and only 19 took clustering into account
in the analysis. Intracluster correlation coefficients and
design effects were reported in only one and three
trials, respectively.20
Extension of CONSORT statement to
cluster trials
To accommodate the reporting of the special features
of the cluster randomised trial, we have extended the
CONSORT statement to include the following
information:
x The rationale for adopting a cluster design
x How the effects of clustering were incorporated into
the sample size calculations
x How the effects of clustering were incorporated into
the analysis
x The flow of both clusters and individuals through
the trial, from assignment to analysis.
Specific changes to the checklist items and the flow
diagram to include these issues are described below.
For items not mentioned here the advice is as for indi-
vidually randomised trials.3
Table 1 shows the modified checklist with the addi-
tions to the standard CONSORT list in italics. In this
section, we discuss the rationale for these extensions
and provide examples of good reporting. In some
examples we have added text in square brackets to
explain the context.
Title and abstract
Item 1: How participants were allocated to interven-
tions (eg random allocation, randomised, or randomly
assigned), specifying that allocation was based on clusters.
Example
Title: “Self help smoking cessation in pregnancy: cluster
randomised trial.”21
Abstract (design): “Pragmatic cluster randomised
controlled trial with community midwife as the unit of
randomisation,”21
Explanation
The primary reason for identifying the design in the
title or abstract is to ensure appropriate indexing of the
study as a cluster randomised trial in Medline. This
indexing ensures ease of identification of these studies
for inclusion in systematic reviews. In addition, readers
will not be misled by apparently large sample sizes.
Researchers should also consider reporting the
number of clusters in the abstract.
Introduction
Item 2: Scientific background and explanation of
rationale, including the rationale for using a cluster design.
Example
Our intention was to enhance the application of evidence by
the whole labour ward team so, to minimise contamination,
the unit of randomisation and analysis was the obstetric unit.22
Explanation
Under the principles of the Helsinki declaration, it is
unethical to expose people unnecessarily to the risks of
research.23 Because a cluster randomised design
increases the complexity of the research and requires
many more participants than an individually ran-
domised design (to ensure equivalent statistical power),
it is particularly important that the rationale for adopt-
ing a cluster design is outlined in the introduction.17
Table 1 Checklist of items to include when reporting a cluster randomised trial
(adaptations from standard guidelines in italic)
Paper section and
topic Item Descriptor
Title and abstract
Design 1* How participants were allocated to interventions (eg random allocation,
randomised, or randomly assigned), specifying that allocation was based on
clusters
Introduction
Background 2* Scientific background and explanation of rationale, including the rationale for
using a cluster design
Methods
Participants 3* Eligibility criteria for participants and clusters and the settings and locations
where the data were collected
Interventions 4* Precise details of the interventions intended for each group, whether they
pertain to the individual level, the cluster level, or both, and how and when
they were actually administered
Objectives 5* Specific objectives and hypotheses and whether they pertain to the individual
level, the cluster level, or both
Outcomes 6* Report clearly defined primary and secondary outcome measures, whether
they pertain to the individual level, the cluster level, or both, and, when
applicable, any methods used to enhance the quality of measurements (eg
multiple observations, training of assessors)
Sample size 7* How total sample size was determined (including method of calculation,
number of clusters, cluster size, a coefficient of intracluster correlation (ICC
or k), and an indication of its uncertainty) and, when applicable, explanation
of any interim analyses and stopping rules
Randomisation:
Sequence
generation
8* Method used to generate the random allocation sequence, including details
of any restriction (eg blocking, stratification, matching)
Allocation
concealment
9* Method used to implement the random allocation sequence, specifying that
allocation was based on clusters rather than individuals and clarifying
whether the sequence was concealed until interventions were assigned
Implementation 10 Who generated the allocation sequence, who enrolled participants, and who
assigned participants to their groups
Blinding
(masking)
11 Whether participants, those administering the interventions, and those
assessing the outcomes were blinded to group assignment. If done, how the
success of blinding was evaluated
Statistical methods 12* Statistical methods used to compare groups for primary outcome(s)
indicating how clustering was taken into account; methods for additional
analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow 13* Flow of clusters and individual participants through each stage (a diagram is
strongly recommended). Specifically, for each group report the numbers of
clusters and participants randomly assigned, receiving intended treatment,
completing the study protocol, and analysed for the primary outcome.
Describe protocol deviations from study as planned, together with reasons
Recruitment 14 Dates defining the periods of recruitment and follow up
Baseline data 15* Baseline information for each group for the individual and cluster levels as
applicable
Numbers analysed 16* Number of clusters and participants (denominator) in each group included
in each analysis and whether the analysis was by intention to treat. State the
results in absolute numbers when feasible (eg 10/20 not 50%)
Outcomes and
estimation
17* For each primary and secondary outcome, a summary of results for each
group for the individual or cluster level as applicable, and the estimated
effect size and its precision (eg 95% confidence interval) and a coefficient of
intracluster correlation (ICC or k) for each primary outcome.
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including
subgroup analyses and adjusted analyses, indicating those prespecified and
those exploratory
Adverse events 19 All important adverse events or side effects in each intervention group
Discussion
Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources
of potential bias or imprecision and the dangers associated with multiplicity
of analyses and outcomes.
Generalisability 21* Generalisability (external validity) to individuals and/or clusters (as relevant)
of the trial findings
Overall evidence 22 General interpretation of the results in the context of current evidence
*Addition to CONSORT guidelines 20012
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Methods
The main difference when reporting a cluster trial, as
opposed to an individually randomised trial, is that
there are two levels of inference rather than one: the
cluster level and the individual level.24 Thus, to allow
readers to interpret the results appropriately, it is
important to indicate explicitly the level at which the
interventions were targeted, the hypotheses were
generated, the outcomes were measured, and random-
isation was done.
Participants
Item 3: Eligibility criteria for participants and clusters
and the settings and locations where the data were
collected.
Example
The study comprised 41 practices in Wessex . . . Inclusion
criteria were ≥ 4 medical partners; list size > 7000; a
diabetes register with > 1% of practice population; and a
diabetes service registered with the health authority . . .
Nurses reported all new cases of diabetes to the trial office.
Willing patients aged 30-70 were included in the trial.
Patients were excluded if they were private patients,
housebound, mentally ill, had severe learning difficulties, or
were subsequently found to have been diagnosed previously
with, or not to have, diabetes, or were found to have type 1
diabetes.25
Explanation
Because there are two levels of inference, the eligibility
criteria for clusters, as well as participants, need to be
reported. In a cluster trial, the primary eligibility crite-
rion is often all the clusters in a defined geographical
area.
Intervention
Item 4: Precise details of the interventions intended for
each group, whether they pertain to the individual level, the
cluster level, or both, and how and when they were
actually administered.
Example
We . . . paired the 14 [urban sectors of Trujillo, Venezuela]
according to the incidence of cutaneous leishmaniasis in the
12 months before the baseline household survey. For each
of the seven pairs we randomly allocated one sector . . . to
the intervention group and the other to the control group
. . . In the intervention group the windows of all 241 houses
(with a total of 1336 inhabitants) were covered with loosely
hanging polyester curtains impregnated with the pyrethroid
insecticide . . . In the 222 houses in six of the control sectors
the windows were covered with non-impregnated curtains
and in one randomly selected control sector with 106
houses no curtains were provided.”26
Explanation
Again, if the intervention was targeted at the cluster
level, specific details of how it was administered should
be described.
Objectives
Item 5: Specific objectives and hypotheses, and whether
they pertain to the individual level, the cluster level, or both.
Example
We aimed to compare the effectiveness of three different
interventions for improving the secondary preventive care
for patients with coronary heart disease delivered at the
level of general practice.27
Explanation
Descriptions of specific objectives and hypotheses
need to make it clear whether they pertain to the indi-
vidual level, the cluster level, or both. Knowing the level
of inference will subsequently aid interpretation of the
statistical methods.
Outcome
Item 6: Report clearly defined primary and secondary
outcome measures, whether they pertain to the individual
level, the cluster level, or both, and, when applicable, any
methods used to enhance the quality of measurements
(eg multiple observations, training of assessors).
Example
We evaluated the effect of a computer based clinical decision
support system and cardiovascular risk chart [both targeted
at physicians—that is, clusters] on patient centred outcomes
of absolute cardiovascular risk and blood pressure.28
Explanation
Whether an intervention is evaluated at the cluster
level or the participant level has implications for the
appropriate analysis of the outcome data. It is
therefore important that the level at which outcomes
are measured be explicit in the trial report.
Sample size
Item 7: How total sample size was determined (includ-
ing method of calculation, number of clusters, cluster size, a
coefficient of intracluster correlation (ICC or k), and an indi-
cation of its uncertainty) and, when applicable, explana-
tion of any interim analyses and stopping rules.
Example
We calculated sample size with a method that takes into
account the intracluster correlation coefficient, the number
of events, the expected effect, and the power of the study.
We assumed an intracluster correlation of  = 0.2, a
minimum of 25 patients for each practice, and a worst case
control rate of 50%. Under these assumptions we
anticipated a power of 87% to detect a difference of 15% in
rates between the two groups with  = 0.05 with 60
practices for each intervention group.29
Explanation
A principal difference between a cluster randomised
trial and an individually randomised trial is the calcula-
tion of the sample size. As indicated above, to retain
equivalent power to an individually randomised trial,
the number of individuals in a cluster randomised trial
needs to be increased. The key determinants of the
increase required are the intracluster correlation and
the cluster size. Reports of cluster randomised trials
should state the assumptions used when calculating
the number of clusters and the cluster sample size.
Sequence generation
Item 8: Method used to generate the random
allocation sequence, including details of any restriction
(eg blocking, stratification, matching).
Example
To help ensure comparability of the intervention and com-
parison communities with respect to baseline HIV and STD
prevalences and risk factors for infection, the communities
were matched into six pairs according to the following crite-
ria: roadside, lakeshore, island, or rural location; geographi-
cal area (paired communities were generally in the same
Education and debate
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district and less than 50 km apart); and prior STD
attendance rates at the health centre.30
Explanation
Cluster randomised trials may use a simple, completely
randomised design; a matched cluster design; or a
stratified design. In individually randomised trials
random assignment generally ensures that any
baseline differences in group characteristics are the
result of chance rather than some systematic bias.31
This cannot be assumed, however, for the cluster
randomised trial.
Although the assumption holds for cluster specific
characteristics (that is, characteristics of the randomly
allocated clusters), the researcher has little control over
the individuals within each cluster7 and the number of
clusters is usually relatively small. As a result, some
form of constraint (matching or stratification) is often
imposed on randomisation in a cluster randomised
design in an attempt to minimise imbalance across
treatment groups. Any constraint imposed on the clus-
ter randomised trial affects the sample size and the
analysis and thus should be reported.
Allocation concealment
Item 9: Method used to implement the random alloca-
tion sequence, specifying that allocation was based on clus-
ters rather than individuals and clarifying whether the
sequence was concealed until interventions were
assigned.
Example
Practices agreeing to participate were . . . assigned by simple
random allocation to use the computer decision support
system . . . Randomisation was performed with a table of
random numbers by a researcher not involved in the study
and who was blind to the identity of the practices.28
Explanation
In individually randomised trials, adequate conceal-
ment of the treatment allocation is crucial to minimis-
ing potential bias. If the person recruiting participants
has foreknowledge of the allocation, bias can result.32 In
a cluster randomised trial, allocation of treatment is
predetermined for each member of the cluster. Hence
the potential for selection bias (selective inclusion of
patients into the trial) within clusters is particularly
high.4 5 It is, therefore, particularly important that
authors outline any strategies that were implemented
to minimise the possibility of selection bias—for exam-
ple, whether all patients within a cluster were included,
or, if not, whether recruitment of patients was by a per-
son masked to the cluster allocation.
Statistical methods
Item 12: Statistical methods used to compare groups
for primary outcome(s) indicating how clustering was
taken into account; methods for additional analyses, such
as subgroup analyses and adjusted analyses.
Examples
Because we randomised obstetric units . . . we analysed rates
of marker clinical practices by obstetric units.22
We used cluster specific methods because practices rather
than patients were randomised . . . We used hierarchical
logistic regression.29
Explanation
Identification of the level of inference allows readers to
evaluate the methods of analysis. For example, if the
intervention was targeted at the cluster level (at general
practitioners rather than patients, for example) and
outcomes were aggregated at the cluster level, sophisti-
cated cluster adjusted analyses are not needed (as in
the first example above). If outcomes were measured at
the individual patient level, however, the analysis would
need to adjust for potential clustering in the data (as in
the second example above).
Results
Participant flow
Item 13: Flow of clusters and individual participants
through each stage (a diagram is strongly recom-
mended). Specifically, for each group report the num-
bers of clusters and participants randomly assigned,
receiving intended treatment, completing the study
protocol, and analysed for the primary outcome.
Describe protocol deviations from study as planned,
together with reasons.
Explanation
Knowing how many clusters and individuals did not
receive the intervention as planned, the proportion
dropping out, and the proportion for whom follow up
data were not available is essential to interpret the
study accurately. For example, individuals excluded
after random assignment may not be representative of
all participants in the study, and different drop-out
rates may be directly related to the treatment received
(if, say, one treatment has more severe side effects).33
The potential for differential adherence and follow up
is exacerbated in the cluster randomised design
because there are two levels at which drop-outs can
occur: whole clusters or individuals in a cluster. It is
therefore important to describe the flow of both
clusters and individuals when reporting a cluster
randomised trial. A flow diagram is usually the best way
to present this information (see below).
Baseline data
Item 15: Baseline information for each group for the
individual and cluster levels as applicable.
Table 2 Example of baseline information for each group given at individual and cluster
levels (adapted from Feder et al34)
Intervention group Control group
Practice factors at baseline
No 25 27
List size:
Low (<1600) 8 10
Medium (1600-2200) 8 10
High (>2200) 9 7
Practice nurse:
No 8 11
Yes 17 16
Patient factors at baseline
No 172 156
Mean age (years) 66.4 64.8
No (%) men 107/172 (62) 87/156 (56)
No (%) of smokers 68/161 (42) 49/141 (35)
No (%) with myocardial infarction 103/172 (60) 91/156 (58)
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Example
See table 2.
Explanation
Random assignment by individual ensures that any
differences in group characteristics at baseline are the
result of chance rather than some systematic bias.32
This assumption does not hold, however, for cluster
randomised trials. It is important to present summary
baseline information for both clusters and individuals,
most simply as tables of summary data.
Numbers analysed
Item 16: Number of clusters and participants (denomi-
nator) in each group included in each analysis and
whether the analysis was by intention to treat. State the
results in absolute numbers when feasible (eg 10/20
not 50%).
Example
See table 3.
Explanation
The number of participants who contribute to the
analysis of a trial is essential to interpreting the results.
Not all participants, however, may contribute to the
analysis of each outcome. In a cluster trial, this fact is
compounded by the possibility that not all clusters may
contribute to a particular analysis. Because the sample
size calculation, and hence the power of the study, is
calculated on the assumption that all participants and
(especially) all clusters will provide information, the
number of participants and clusters contributing to a
particular analysis should be reported so that any
potential drop in statistical power can be assessed. The
flow diagram can include this information if there is
only one primary outcome; otherwise the numbers of
participants and clusters contributing should be
summarised for each outcome.
Outcomes and estimation
Item 17: For each primary and secondary outcome, a
summary of results for each group for the individual or
cluster level as applicable, and the estimated effect size
and its precision (eg 95% confidence interval) and a
coefficient of intracluster correlation (ICC or k) for each
primary outcome.
Example
See table 3.
Explanation
When reporting the results of a cluster randomised
trial, point estimates with confidence intervals should
be reported for primary outcomes. Given the impact
of the extent of the intracluster correlation on the
power of the study, the intracluster correlation
coefficient or k statistic, for each outcome being
analysed should also be provided. This information
will allow readers to assess the appropriateness of the
original sample size calculations as well as the magni-
tude of the clustering for each outcome. Showing both
adjusted and unadjusted estimates would provide
another indication of the extent of the clustering. Sev-
eral authors have advocated publishing intracluster
correlation coefficients to allow them to inform the
development of future cluster trials in similar
settings.9 35–37
Discussion
Item 21: Generalisability (external validity) to individu-
als and/or clusters (as relevant) of the trial findings.
Example
Although our trial was completed successfully from both a
methodological and practical point of view, our results may
not be generalisable. The 21 participating practices tended
to be large, with good nursing support, and may have been
particularly committed to improving their quality of care . . .
Table 3 Example of study including data on numbers analysed by cluster and intracluster correlation coefficients (adapted from Feder
et al34)
Variable
Intervention
No (%)
Control
No (%)
Intracluster
correlation
coefficient
Adjusted odds ratio
(95% CI)
Adjusted 2
statistic P value
No of practices 25 27
No of patients 172 156
Advice given:
Cholesterol 54/81 (67) 32/83 (39) 0.013 4.0 (1.9 to 8.2) 12.2 <0.001
Weight 74/169 (44) 32/154 (21) 0.098 3.0 (1.5 to 35.8) 10.5 <0.01
Diet 46/169 (27) 22/154 (14) 0.053 2.4 (1.2 to 4.7) 6.2 <0.05
Assessed for eligibility (No of clusters)
Excluded (No of  clusters):
 Not meeting inclusion criteria (No of  clusters)
 Refused to participate (No of  clusters)
 Other reasons (No of  clusters)
Randomised (No of clusters)
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lo
ca
tio
n
Fo
llo
w
 u
p
An
al
ys
is
En
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t
Allocated to intervention (No of clusters)
 Received allocated intervention
  (No of clusters, average cluster size,
  range of cluster size)
 Did not receive allocated intervention; give
  reasons (No of clusters, average cluster size,
  range of cluster size)
Lost to follow up; give reasons
 (No of clusters, average cluster size,
  range of cluster size)
Discontinued intervention; give reasons
 (No of clusters, average cluster size,
 range of cluster size)
Analysed
 (No of clusters, average cluster size,
  range of cluster size)
Excluded from analysis; give reasons
 (No of clusters, average cluster size,
 range of cluster size)
Allocated to intervention (No of clusters)
 Received allocated intervention
  (No of clusters, average cluster size,
  range of cluster size)
 Did not receive allocated intervention; give
  reasons (No of clusters, average cluster size,
  range of cluster size)
Lost to follow up; give reasons
 (No of clusters, average cluster size,
  range of cluster size)
Discontinued intervention; give reasons
 (No of clusters, average cluster size,
 range of cluster size)
Analysed
 (No of clusters, average cluster size,
  range of cluster size)
Excluded from analysis; give reasons
 (No of clusters, average cluster size,
 range of cluster size)
Fig 1 Recommended format for flow diagram of the progress of clusters and individuals
through the phases of a randomised trial
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Furthermore, the observed intervention effect would
probably have been greater if the trial had not taken place in
the context of a health authority audit initiative relating to
patients with coronary heart disease, backed by a financial
incentive.”27
Explanation
In the discussion section of any trial report, the
external validity of the results should be considered.
External validity is more complicated for cluster
randomised trials because the results may be generalis-
able to the clusters, to the individuals in those clusters,
or to both, and thus the level at which external validity
is addressed should be identified.
Flow diagrams
We previously presented three options for modifying
the CONSORT flow diagram for presenting clustered
data: presenting the flow of data based only on clusters,
only on individual participants, or both.8 Further
experience suggests that the type of diagram should
depend on the type of analysis because different
approaches to analysis require information at different
levels of the clustered design.
For example, if the analysis is aggregated at the
level of the cluster, the flow diagram should relate to
the cluster level data (fig 1). To allow meaningful
interpretation, a measure of the cluster size (and an
indication of how variable cluster sizes are) also needs
to be included in the diagram. If, however, the analysis
is multilevel or hierarchical, the flow diagram should
present data flow for both clusters and individual
participants (fig 2).
Although we recommend this diagram for commu-
nicating the flow of clusters and participants through-
out the study, the exact form and content of the flow
diagram should be varied to present the specific
features of a trial.
Comments
Reports of cluster trials should include key infor-
mation on the design and analysis to allow readers to
accurately interpret the results. This information is also
particularly important for meta-analysts attempting to
extract data from such reports.39 We therefore
recommend that journal editors include our guidelines
in their instructions to authors.
Inadequate methodological reporting of trials has
been shown to be associated with bias in the estimate
of treatment effects.40 Use of the CONSORT statement
for the reporting of two group parallel trials is
associated with improved reporting quality.41 42 43 We
believe that the routine use of this proposed extension
to the CONSORT statement will result in similar
improvements for cluster trials.
The CONSORT group is also developing modified recommen-
dations to help improve the quality of reporting of clinical trials
of other designs, including equivalence trials, crossover trials
and multi-arm trials. The most up to date versions of all CON-
SORT recommendations can be found at www.consort-
statement.org. We thank the members of the CONSORT
Group, especially David Moher, Ken Schulz, Tom Lang, David
Sackett, Peter Gøtzsche, Matthias Egger, and John Ioannidis for
helpful comments on earlier drafts. The Health Services
Research Unit is funded by the Chief Scientist’s Office of the
Scottish Executive Health Department. DGA is supported by
Cancer Research UK. The views expressed are not necessarily
those of the funding bodies.
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Q&A
Blocked ears and flying
Question
What options are available to relieve ear blockage due to flight
descents, apart from chewing gum, taking Sudafed tablets if you
have a cold, or yawning?
Parthasarathy Ramesh, consultant physician, Solihull Hospital,
Solihull
Answer
Blowing up a balloon is great for cooperative kids.
John McCormack, general practitioner, Connemara, Republic of
Ireland
Answer
Nothing scientific here—drink water. I find that, if I drink water as
I ascend or descend on my flights, it helps dramatically. In
addition to relieving that dreaded pain, it also keeps you
hydrated. Eureka.
Aaron J Baxter, medical student, Saba University, Dutch Antilles
Answer
The “pinch and blow” method is used by descending scuba divers
and is just as effective for descending airline passengers. Occlude
both nostrils by squeezing the end of your nose, then blow hard
through your nose (no air or, er, mucus will escape from your
nose if you’re squeezing hard enough). You’ll feel one ear pop,
then the other—and great relief.
Theo Fenton, consultant paediatrician,Mayday Hospital, Croydon
http://bmj.com/cgi/qa-display/short/bmj_el;42930
These exchanges were posted on the Q&A section of bmj.com. If you want
to respond to the question, or ask a new question of your own, follow the
link above or go to http://bmj.com/q&a
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